What type of study is this?

August 20, 2025Open Access

Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in cancer patients.
Patients with head and neck squamous cell carcinoma achieved complete response after 15 months of therapy.
Assessment involved monitoring tumor fraction using ctDNA across various cancer types including NSCLC and endometrial carcinoma.
Study suggests monitoring tumor fraction may enable more personalized treatment approaches in oncology.

Abstract

A–F, Representative patient examples demonstrating serial monitoring of TF for patients with (A) CR with head and neck squamous cell carcinoma; rwPFS = 15 months. B, SD with NSCLC; rwPFS = 13.77 months. C, SD with endometrial carcinoma; rwPFS = 12.37 months. D, PD with hepatocellular cancer; rwPFS = 5.6 months. E, PD with SCLC; rwPFS = 6.233 months. F, PD with NSCLC; rwPFS = 6.07 months; notably, TF was not detected at baseline.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Samantha I. Liang

Zoe Quandt

Sara Wienke

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider